USA US Congress has highlighted Chinese biotechnology firms, including giants WuXi and BGI, as posing a risk to the country’s national security. PharmaBoardroom takes a look at why the US is now targeting these companies and the potential impact of a proposed US Biosecure Act on US-China biotech ties. Protecting…
China The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in June; the potential of Western China as a manufacturing hub; and EpimAb’s plan for a public stock offering in 2022 amid a booming global bispecific antibodies market. Pharma Not Immune From Coming…
Global COVID-19 has drawn global attention to the sorry state of funding and R&D investment in vaccine development and pandemic prevention, but other previously neglected areas of health research are also now entering the spotlight. One of these underfunded areas is mental health and neurological disorders, leading a global group of…
See our Cookie Privacy Policy Here